The fasting lipid profile does not necessarily illustrate the dynamic features of lipid metabolism over a 24 hour period as human subjects are in the postprandial (PP) state for most of the day. PP triglyceride (TG) measurement in plasma has been reported to have advantages compared to fasting TG in terms of practicality and the ability to predict cardiovascular risk.
Topline SHASTA-3 and SHASTA-4 results show durable TG reductions with plozasiran
The Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridaemia (sHTG) have met their primary endpoint of TG reduction versus placebo and all prespecified secondary endpoints, including a statistically significant reduction in acute pancreatitis (AP) compared to placebo.
Residual risk beyond LDL: A new apoB-centred framework for atherosclerosis
Professor Jan Borén, Institute of Medicine, University of Gothenburg, Sweden, welcomes the timely reframing of apoB biology presented in Professor Chris Packard’s video presentation ‘ApoB and atherosclerosis 2026: Answers and Questions‘, highlighting its importance in moving the field beyond the LDL-centric model to a more integrated view which includes the atherogenic potential and clinical significance of triglyceride-rich lipoproteins and Lp(a).
Risk weighted apoB improves CHD risk stratification
Risk weighted apoB (RW-apoB), a novel measure that integrates the particle number and atherogenic potential of LDL, triglyceride rich lipoprotein (TRL) and Lp(a), more accurately reflects total atherogenic burden and coronary heart disease (CHD) risk than LDL-C, non-HDL-C or apoB alone. This is the conclusion of Professor Jan Borén and colleagues from results with the […]
Hypertriglyceridaemia: Where next for cardiovascular outcomes trials?
Highly effective agents are now available, such as olezarsen and plozasiran, that reduce triglyceride (TG) levels by 60-70% in patients with severe hypertriglyceridaemia (sHTG >5.6-10 mmol/L or 500-880 mg/dL), and there is growing evidence of comparable reductions in patients with moderate hypertriglyceridaemia (mHTG, 1.7-5.6 mmol/L or 150 -499 mg/dL). However, evidence that TG reductions translate into positive CV outcomes is limited.
Tryngolza (olezarsen) is approved for sHTG in USA
The US Food and Drug Administration (FDA) has approved Tryngolza (olezarsen) as an adjunct to diet to reduce TG and the risk of acute pancreatitis in adults with severe hypertriglyceridaemia (sHTG), ie. TG ≥500 mg/dL.
